Ticker Details
Protagonist Therapeutics, Inc. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company with a proprietary peptide-based technology platform focused on discovering and developing new chemical entities to address significant unmet medical needs.
IPO Date:	August 11, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$9.99B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.78 | 3.07%
Avg Daily Range (30 D):	$3.34 | 2.40%
Avg Daily Range (90 D):	$2.80 | 2.38%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	.39M
Avg Daily Volume (90 D):	.45M

Trade Size
Avg Trade Size (Sh.):	70
Avg Trade Size (Sh.) (30 D):	35
Avg Trade Size (Sh.) (90 D):	40

Institutional Trades
Total Institutional Trades:	3,475
Avg Institutional Trade:	$3.76M
Avg Institutional Trade (30 D):	$10.53M
Avg Institutional Trade (90 D):	$10.07M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.82M
Avg Closing Trade (30 D):	$15.39M
Avg Closing Trade (90 D):	$17.41M
Avg Closing Volume:	149.44K

News

Apr 22, 2026 @ 5:00 PM Polycythemia Vera Market Set for Transformation: K... Source: Delveinsight

Apr 2, 2026 @ 10:14 AM This Healthcare Stock Barely Flinches During Marke... Source: James Halley

Mar 19, 2026 @ 12:25 PM Johnson & Johnson-Protagonist Therapeutics Partner... Source: Vandana Singh

Feb 25, 2026 @ 8:28 PM Protagonist Stock Up 120%, but One Fund Just Revea... Source: Jonathan Ponciano

Oct 23, 2025 @ 6:25 PM Moody Aldrich Dumps Entire Stake in Chart Industri... Source: Adam Palasciano

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$1.22	$2.47	$.06
Diluted EPS	$1.03	$2.29	$.05
Revenue	$281.99M	$213.48M	$56.37M
Gross Profit
Net Income / Loss	$82.91M	$162.85M	$3.78M
Operating Income / Loss	$58.34M	$158.77M	$-3.65M
Cost of Revenue
Net Cash Flow	$251.53M	$226.37M	$65.32M
PE Ratio